Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2011

View Archived Issues

GlaxoSmithKline discloses first-in-human data on GSK-2126458 and GSK-2141795

Roche presents new inhibitors of the Mdm2-p53 interaction

Novel hepatocyte growth factor receptor inhibitors patented

Phase II extension trial evaluates continued E-5501 treatment of thrombocytopenia

Phase II ARQ-197 trial assesses safety and efficacy in relapsed/refractory non-CNS germ cell tumors

Pilot study supports tolerability of AC-480 in patients with recurrent malignant glioma

Receptos designs new lysophospholipid S1P1 receptor agonists

Novel chemokine CXCR4 receptor ligands patented

Zealand Pharma and Boehringer Ingelheim join to advance new drugs for type 2 diabetes and obesity

Tradjenta tablets launched in U.S. for type 2 diabetes

BMT-4-159 is a new 17-beta-HSD 5 inhibitor with potential to treat prostate cancer

Orexo completes first clinical study of OX-27 for breakthrough cancer pain

Kareus Therapeutics and Quintiles enter strategic alliance

Data presented from two phase II trials of BCX-4208 with/without allopurinol in gout

AC-201 to enter phase IIb trial in type 2 diabetes

Servier holds option to acquire full Ampakine rights from Cortex Pharmaceuticals

Pronova BioPharma prepares to submit application for PRC-4016 trial in mixed dyslipidemia

New glycogen synthase activators presented

BiondVax reports phase IIa data on Multimeric-001 universal flu vaccine

Sanofi and Audion Therapeutics to develop treatments for hearing loss

MP4OX enters phase IIb trial in patients with trauma and lactic acidosis due to hemorrhagic shock

FDA accepts IntelGenx's resubmission of CPI-300 NDA

Istodax approved in U.S. as therapy for previously treated patients with peripheral T-cell lymphoma

Durasert-based latanoprost delivery implant enters phase I/II trial in patients with elevated IOP

FDA committee to review Seattle Genetic's Adcetris BLAs in July

Bardoxolone methyl enters pivotal trial in patients with chronic kidney disease and type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...